Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 29, 2017
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
Wednesday, January 25, 2017
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Tuesday, January 24, 2017
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam
Wednesday, January 18, 2017
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Monday, January 16, 2017
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
Thursday, January 12, 2017
Eisai to Launch Medication Administration Support Device
Thursday, January 5, 2017
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin
Thursday, December 22, 2016
Eisai and Keio University to Establish a New Industry-Academia Collaboration Site
Tuesday, December 20, 2016
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: